The truncated tau protein is a component of the neurofibrillary tangles found in the brains with tauopathies. However, the molecular mechanisms by which the truncated tau fragment causes neurodegeneration remain unknown. Tau pathology was recently suggested to spread through intercellular propagation, and required the formation of 'prion-like' species. We herein identified a new fragment of the tau protein that consisted of four binding domains and a C-terminal tail (Tau-CTF24), but lacked the N-terminal projection domain, and found that it increased with aging in tauopathy model mice (Tg601). Tau-CTF24-like fragments were also present in human brains with tauopathies. A mass spectroscopic analysis revealed that Tau-CTF24 was cleaved behind R242. The digestion of full-length tau (Tau-FL) by calpain produced Tau-CTF24 in vitro and calpain activity increased in old Tg601. Recombinant Tau-CTF24 accelerated heparin-induced aggregation and lost the ability to promote microtubule assembly. When insoluble tau from diseased brains or aggregated recombinant tau was introduced as seeds into SH-SY5Y cells, a larger amount of insoluble tau was formed in cells overexpressing Tau-CTF24 than in those overexpressing Tau-FL. Furthermore, lysates containing the Tau-CTF24 inclusion propagated to naive tau-expressing cells more efficiently than those containing the Tau-FL inclusion. Immunoblot and confocal microscopic analyses revealed that aggregated Tau-CTF24 bound to cells more rapidly and abundantly than aggregated Tau-FL. Our results suggest that Tau-CTF24 contributes to neurodegeneration by enhancing prion-like propagation as well as deteriorating the mechanisms involved in microtubule function.
Introduction
Tau is an abundant microtubule (MT)-associated protein in the central nervous system that has been implicated in the pathogenesis of neurodegenerative diseases known as tauopathies including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and frontotemporal lobar degeneration (FTLD) (1) . The primary function of tau, which is mainly localized in the axons of neurons, is to promote the assembly of and stabilize MTs. Tau proteins have been shown to undergo several post-translational modifications including phosphorylation and truncation during normal development as well as in the AD brain (2, 3) . Phosphorylation is typically regarded as one of the most important changes in tau. An increase in the phosphorylation of tau was previously reported to negatively regulate MT binding, which may ultimately result in impaired axonal transport (1, 4, 5) . In addition to the well-known changes in its phosphorylation state, a number of studies reported that the tau proteolysis, leading to truncation, might play an important role as an early step in neurodegeneration (6) (7) (8) .
Truncated forms of tau proteins have been shown to contribute to the pathological assembly of fibrillar structures in AD (6, 7) . The 12-kDa fragment of tau was previously purified from neurofibrillary tangles and epitope mapping revealed that the monoclonal antibody, mAb 423, recognized the tau protein C-terminally truncated at Glu 391 (Numbering according to the longest form of human tau) (9, 10) . A transgenic mouse model expressing human tau truncated at Glu 391 exhibited pretangle pathological changes in tau including the accumulation of insoluble tau, phosphorylation of tau and somatodendritic redistribution of tau (11) . Despite that contribution, no candidate enzyme has been proposed to produce this cleavage in the tau molecule. Tau was previously shown to be proteolyzed by caspase 3 at Asp 421 in its C-terminus when treated with the amyloid-β peptide, and the truncated protein, which lacked 20 amino acids in its C-terminal, assembled more rapidly and more extensively into tau filaments (12) . Tau truncated at Asp 421 , as observed in neurofibrillary tangles (12) and in the brains of mice transgenic for mutant human P301S tau truncated tau at Asp
421
, was detected at low levels in the Tris-soluble (TS) and detergent-soluble fractions of AD-affected brains (13) . Although cell culture experiments indicated that the activation of caspase and caspase-cleaved products caused apoptotic cell death (12, 14) , multiphoton imaging of the living rTg4510 mouse brain revealed that caspase-positive cell bodies did not degenerate (15) . Recent studies demonstrated that the secretion of tau cleaved at Asp 421 from Hela cells was significantly greater than that of full-length tau (Tau-FL) (16) ; however, neuronal cells were not examined.
The hypothesis that tau may be propagated by a prion-like mechanism was attributed to the network-based spread of neurofibrillary tangles (17) . An injection of brain extracts from mutant mice into the brains of transgenic wild-type tau-expressing animals induced tau filaments and the spread of tau pathology (18) . Brain homogenates from human tauopathies were also shown to form argyrophilic tau inclusions following an injection of the corresponding brain extracts into the rodent brain (19) . The intracerebral inoculation of mice expressing P301S mutated tau with synthetic tau fibrils in the presence of heparin resulted in the induction of NFT-like inclusions and spread of tau pathology (20) . Unilateral infusion with a brain extract containing tau aggregates into P301S tau transgenic mice revealed that this spread was dependent on synaptic connectivity rather than spatial proximity (21) . In vitro experiments also showed that recombinant tau aggregates entered C17.2 cells and induced the fibrillization of intracellular-transfected tau (22) . Furthermore, the introduction of α-synuclein or four-repeat tau fibrils into SH-SY5Y cells with a transfection reagent generated extensively phosphorylated and ubiquitinated inclusions (23) . Paired helical filaments extracted from the AD brain developed intracellular tau aggregates that possessed the attributes of aggresomes (24) . Tau was also previously reported to be secreted into the extracellular culture medium of non-neuronal (25) or neuronal cell lines via an unconventional mechanism such as that involving exosomes (26, 27) . The stimulation of neuronal activity induced the release of tau (28) while the blockade of pre-synaptic vesicles impaired it (29) . Starvation and the inhibition of lysosomal function also increased the tau-enhanced secretion of tau (30) .
In the present study, we attempted to elucidate the posttranslational modifications in tau that increased with age in a tauopathy model, the Tg601 mouse, which expressed wild-type human tau and was generated by us (31) . Anxiety behavior in the elevated plus maze test was decreased in old Tg601 mice (>16-months); however, the increase observed in tau phosphorylation with aging was small. We identified a 24-kDa tau C-terminal fragment (Tau-CTF24) truncated behind Arg 242 lacking the N-terminal half including the projection domain. In spite of the preservation of four MT-binding repeat regions, recombinant Tau-CTF24 showed loss of ability to promote MT assembly and the loss of bundling capacity in cultured cells. We also demonstrated that Tau-CTF24 had higher aggregating activity and bound to cell surfaces more efficiently than Tau-FL.
Results
The truncated 24-kDa C-terminal fragment of tau increased with aging in Tg601 mice
To elucidate a model of sporadic tauopathy, we created Tg601 mice overexpressing wild-type human tau (2N4R) that developed hyperphosphorylated-tau, the loss of anxiety and synapse loss with aging (31) . However, since the elevation in tau phosphorylation with aging was not so prominent, we decided to investigate other post-translational modifications in tau that may have led to these aging abnormalities. We performed western blotting of sequentially extracted tau from young (1-2 month-old) and old (18-20 month-old) Tg601 mouse brains using the TauC antibody, which recognizes the C-terminal end of tau (Fig. 1A) , and carefully compared the band patterns between the young and old mouse groups. We found the C-terminal 24-kDa fragment of tau (Tau-CTF24) was more abundant in the Ts and TritonX-soluble (Tx) fraction from brains of old Tg601 mice than in those of young Tg601 mice ( Fig. 1B and C, arrow). When we compared Tau-CTF24 between Non-Tg and Tg601 mice at the same age, larger amounts of Tau-CTF24 were detected in the Tg601 mouse group than in the Non-Tg mice group. In the Tx-sup, Tau-CTF24 was more abundant in old than in young Tg601 and Non-Tg mice ( Fig. 1C and E) . Tau-CTF24 in the sarkosyl-soluble (Sar) and pellet ( ppt) fractions was not apparently detected in the mouse brain samples, however, faint 20-25 kDa bands were present only in the old Tg601 brain samples (Supplementary Material, Fig. S1A and B). We performed an immunoblot analysis using 5 tau antibodies (Fig. 1A ) that recognize various exons in order to identify the truncated amino-terminal region of Tau-CTF24. Tau N and Tau-5 antibodies did not stain Tau-CTF24 ( Fig. 1F and G) , whereas Exon10v2 and T46 did ( Fig. 1H and I ). These results indicated that Tau-CTF 24 was cleaved close to exon 9 and included the C-terminal.
C-terminal tau fragments with similar epitopes of Tau-CTF24 were present in human tauopathies
To determine whether Tau-CTF24 was present in human tauopathy brains, western blotting was performed on sequentially extracted brain samples including AD, familial FTLD with the N279K mutation, PSP and CBD using TauN, Tau5, Exon10v2 and TauC antibodies. TauN and Tau-5 antibodies did not detect any bands close to the 24-kDa bands ( Fig. 1J and K) , whereas Exon10v2 and TauC antibodies stained multiple bands between the 20 and 28 kDa bands ( Fig. 1L and M, arrow, Supplementary Material, Fig. S1C and D) . These epitopes were same as those for Tau-CTF24. In the AD brain, the TauC antibody detected three Cterminal fragments, mainly in Tx-sup, Sar-sup and ppt (Fig. 1M,  Supplementary Material, Fig. S1D ). In 4R tauopathies such as familial (FTLD) with the N279K mutation, PSP and CBD, two C-terminal fragments were present at large amounts in Sar-sup and ppt and small amounts in Ts-sup. Tau-FL bands (droplets of 64 and 68 kDa) were also recognized in AD (72, 68, 64 and 60 kDa) and 4R tauopathies (68 and 64 kDa). Since the tau of AD consisted of 3R and 4R tau, the number of cleaved C-terminal fragments may have been higher in AD than in 4R tauopathies.
Tau-CTF24 in the Tg601 mouse brain was truncated behind R242
To identify the truncation site of tau, the Tau-CTF24 band from the Tg601 mouse brain was excised (Supplementary Material, Fig. S2A ) and digested with trypsin, and the resulting peptides were subjected to liquid chromatography-ion trap mass spectrometry (LC-MS). As shown in Supplementary Material, Figure  S2B , the MS/MS analysis identified 12 peptides including LQTAPVPMPDLK in the Tau-CTF24 band. These peptides located between L243 and K438 (Supplementary Material, Fig. S2C ). Other peptides corresponding to 1-242 regions were not detected using V8 or chymotrypsin. The peptide LQTAPVPMPDLK was one of the main products obtained from trypsin digests. Therefore, we determined this peptide as an N-terminal peptide. These results were consistent with those of the western blotting analysis using various anti-tau antibodies. Therefore, we concluded that the amount of Tau-CTF24 increased in the Tg601 mouse brain with aging and was cleaved behind R242.
Recombinant truncated Tau-CTF24 exhibited higher aggregation activity and lower MT assembly activity than Tau-FL
We prepared recombinant full-length 2N4R tau (Tau-FL) and Tau-CTF24 (residues L243-L441) to characterize tau truncation behind Human Molecular Genetics, 2015, Vol. 24, No. 22 | 6405 R242 ( Fig. 2A) . Previous studies reported that the N-or C-terminal region of tau was required to stabilize paperclip conformations in order to protect against aggregation (8, 32, 33) . We performed a heparin-induced tau fibrillization assay using these recombinant proteins to determine whether the absence of the N-terminal projection domain affected the solubility of tau. As expected, Thioflavin S (ThS) fluorescence by Tau-CTF24 was approximately 4-fold higher than that by equal moles of Tau-FL ( Fig. 2B and C) . These results indicated that Tau-CTF24 accelerated aggregation activity into filaments more than Tau-FL. On the other hand, we speculated that Tau-CTF24 maintained MT assembly function because all MT-binding repeats were preserved. However, contrary to our expectation, the MT assembly assay revealed that the ability of Tau-CTF24 to promote MT assembly was weaker than that of Tau-FL (Fig. 2D ). To evaluate the functional significance of tau truncation at R242, the Tau-CTF24 protein was expressed in N2a cells ( These results suggested that Tau-CTF bound to MT with lower affinity than Tau-FL, consistent with previous reports (35, 36) , and caused functional impairments by reducing MT stabilization even though MT-binding repeats remained in Tau-CTF24.
Calpain could be responsible for Tau-CTF24 production
Previous studies demonstrated that alterations in calcium homeostasis in AD pathogenesis were associated with the overactivation of calpain (37, 38) , and this was correlated to the number of NFTs (39) . Therefore, we investigated whether calpain produced Tau-CTF24 in vitro and in cultured cells. Digestion of the recombinant Tau-FL with calpain 1 (30 units/mg) mainly generated Tau-CTF24-like fragments that were recognized by Exon10v2 and TauC, but not by TauN or Tau5 ( Fig. 3A-D) . In order to confirm that calpain 1 specifically cleaved tau protein, we performed an in vitro calpain cleavage assay using Tau-FL-overexpressing SH-SY5Y cell lysates. The amount of Tau-FL decreased in a concentration-dependent manner in the presence of calpain 1; an excess of calpain 1 completely digested tau while 15 and 60 units/ml of calpain 1 generated the Tau-CTF24 fragment (Fig. 3E) . Furthermore, calpain-dependent tau cleavage (40) (Fig. 3F and G) . Although a small amount of Tau-CTF24 was detected in the lysate even without the calpain treatment, this may have been because tau was endogenously cleaved by calpain. Therefore, we concluded that calpain could cleave tau proteins and produce Tau-CTF24. To determine whether calpain activity was increased with aging in Tg601 mice, we performed biochemical and immunohistological analyses to investigate the status of calpain in the Tg601 mouse brain using specific antibodies against p35 (putative calpain substrate), calpastatin (endogenous calpain inhibitor: CAST), calpain-cleaved spectrin (136kf) (41) and post-calpain 1 (activated calpain1) (42, 43) . As shown in Figure 3H , a western blotting analysis of brain extracts using the p35 antibody (C-19) revealed significantly decreased levels of p35 and p25 in the brains of old Non-Tg and Tg601 mice ( Fig. 3H-J) . CAST levels were lower in the brains of old Tg601 mice than in those of young Tg601 mice; however, no significant difference was observed between young and old Non-Tg mice ( Fig. 3H and K) . We then performed an immunohistochemical analysis to determine the localization of activated calpain-1 (Fig. 3M) . The antibody for activated calpain 1 immunostained neuronal cell soma in CA3 of the hippocampus in the mouse brain (Fig. 3M) . Calpain 1 immunoreactivity increased with aging in Tg601 mice while Non-Tg mice did not exhibit any aging differences ( Fig. 3M and N) . Therefore, these results suggested that calpain activity increased with aging and might contribute to age-dependent increases in the amount of Tau-CTF24.
Tau-CTF24 has higher aggregation activity to various kinds of seeds than Tau-FL
The high heparin-induced aggregation activity of Tau-CTF24 in vitro suggested that Tau-CTF24 may have high seeding activity. Therefore, we compared the seeding activity of fibrils in the Tau-FL, Tau-CTF24 or sarkosyl-insoluble fraction of diseased brains using a cellular model of intracellular tau aggregate formation (23) . SH-SY5Y cells expressing Tau-CTF24 or Tau-FL were exposed for 6 h to various seeds including heparin-induced assembled Tau-FL, Tau-CTF24 or sarkosyl-insoluble pellets from human tauopathies (Fig. 4) . The medium was then exchanged and the incubation was continued for a further 48 h. Expressed tau was recruited into the TS-sup and ppt, as detected by the phosphorylation-dependent antibody, PS396 (Fig. 4A) . The results obtained showed that, in cells overexpressing Tau-FL (Fig. 4A left panel) , the seeding activity of Tau-CTF24 was lower than that of Tau-FL. However, cells overexpressing Tau-CTF24 showed greater aggregation to various seeds in the ppt fraction than those overexpressing Tau-FL, whereas TS Tau-CTF24 expression levels were lower than those of Tau-FL ( Fig. 4A and B) . These results indicated that Tau-CTF24 aggregated more easily than Tau-FL when they were exposed to the same levels of tau seeds. When we compared seeding activity between aggregated recombinant tau and sarkosyl-insoluble ppt from human tauopathies, sarkosyl-insoluble ppt from tauopathies brain formed higher amount of ppt (Fig. 4B) . The same results were obtained for phosphorylated-tau-dependent antibodies including anti-PS396 and 12E8 (Fig. 4C-F) . Furthermore, negative stain electron microscopic analyses of ppt of cells with the tau plasmid and various seeds revealed transfected anti-PS396-positive tau filaments with a width of 15 nm (Fig. 5A and Supplementary Material, Fig. S4 ). Confocal microscopic examinations showed the presence of phosphorylated-tau positive intracellular inclusions in SH-SY5Y cells exposed to sarkosyl ppt seeds from AD brains while only a diffuse cytoplasmic staining pattern was observed in SH-SY5Y cells overexpressing Tau-FL or Tau-CTF24 without seeds (Fig. 5B) . PS396-positive inclusions were detected as puncta and sometimes occurred multiple times in each cell. Quantitative image analysis revealed that SH-SY5Y cells overexpressing Tau-CTF24 exhibited higher percentage of cells bearing PS396-positive puncta than those overexpressing Tau-FL (Fig. 5C ). Forming of tau inclusions in seeded cells was also confirmed using anti-ubiquitin antibody and ThS (Supplementary Material, Fig. S5 ). Seeds from AD brain induced intracellular inclusions more efficiently than aggregated recombinant seed. These immunohistochemical findings are consistent with the data of immunoblotting.
Tau-CTF24 transfer aggregated conformations more efficiently than Tau-FL
In order to compare the propagation efficiency of Tau-FL and Tau-CTF24, we transduced cell lysates containing inclusions into SH-SY5Y cells expressing Tau-FL or Tau-CTF24, as described in Figure 6A . In Tau-CTF24-expressing SH-SY5Y cells, the cell lysate containing Tau-CTF24 aggregates induced by AD seed transduction (CTF AD Lys) showed significantly higher propagation Human Molecular Genetics, 2015, Vol. 24, No. 22 | 6409 efficiency than that containing Tau-FL aggregates (FL AD Lys) ( Fig. 6B and C) . Although similar changes were observed in Tau-FL-expressing cells, they were not significant ( Fig. 6B and C) .
Tau-CTF24 aggregates attached to the cell surface more efficiently than Tau-FL aggregates
We hypothesized that the high seeding activity of Tau-CTF24 was attributed not only to a strong aggregation capacity, but also to its rapid attachment to the cell surface. In order to determine whether Tau-CTF24 was transferred into cells more efficiently than Tau-FL, SH-SY5Y cells were treated with 50 nM of monomeric Tau-FL, aggregated Tau-FL, monomeric Tau-CTF24 or aggregated Tau-CTF24 without any transfection reagents. Aggregated Tau-CTF24 was detected in the lysate fraction as well as the sarkosylinsoluble fraction 5 min after its addition, whereas tau monomers and aggregated Tau-FL were not (Fig. 7A) . A confocal laser microscope analysis revealed that aggregated Tau-CTF24 attached to the cell surface more abundantly than Tau-FL and aggregated tau binding was inhibited in the presence of 10 µg/ml heparin ( Fig. 7B and C) . This result was consistent with previous findings in which heparin sulfate proteoglycans (HSPGs) mediated aggregated tau protein binding (44) . Taken together with the results of the present study, these findings suggest that aggregated Tau-CTF24 bound more efficiently to SH-SY5Y cells and may induce further aggregation more than aggregated Tau-FL.
Discussion
In the present study, we identified a novel C-terminal fragment of tau, Tau-CTF24, in Tg601 mice overexpressing wild-type human tau that were generated by us (31) . The amount of Tau-CTF24 increased with aging in the Tg601 mouse brain and Tau-CTF24-like fragments were detected in human tauopathies. Western blotting and MS/MS analyses revealed that Tau-CTF24 was cleaved behind R242 and lost the N-terminal projection domain. We demonstrated that Tau-CTF24 had both 'loss-of-function' and 'gain-of-function' phenotypes, i.e. a marked reduction in the ability to promote MT assembly and enhanced aggregation activity into filaments. The in vitro digestion of recombinant tau protein with calpain 1 and the calpain cleavage assay using SH-SY5Y lysates indicated that calpain-1 was the enzyme responsible for producing Tau-CTF24. Our experiments with seed-transfected SH-SY5Y cells overexpressing Tau-FL or Tau-CTF24 demonstrated that intracellular Tau-CTF24 formed phosphorylated-tau inclusions more abundantly than Tau-FL. Additively, aggregated synthetic Tau-CTF24 attached to the cell surface more rapidly and robustly than aggregated Tau-FL. Moreover, cells transfected with Tau-CTF24 secreted more exosome-associated tau into the extracellular medium than cells expressing Tau-FL. These results suggested that the amount of calpaincleaved tau increased with age and promoted prion-like propagation in brains with tauopathies.
We demonstrated that Tau-CTF24 lacking the projection domain was prone to aggregation, which was consistent with previous findings (45 -47) . The N-terminal region flanking the MT-binding domain of tau was inhibitory to self-assembly into filaments. Thus, the neutralization of this inhibitory domain in part by truncation may result in the formation of neurofibrillary tangles (2) . In addition, Tau-CTF24 exhibited weaker activity in the MT assembly assay than Tau-FL in vitro. The MT bundling activity of Tau-CTF24 was significantly weaker than that of Tau-FL, even in N2a cells. The overexpression of Tau-FL was previously shown to stabilize MTs and promote MT bundling in cultured cells (48) whereas the phosphorylation (34) or acetylation (49) of tau showed reduced MT bundling activity. Therefore, the elimination of 1-242 residues in tau may be as harmful to MT assembly as phosphorylation and acetylation. In vitro investigations of the tau regions that affect MT assembly using a recombinant protein demonstrated that the N-terminal projection domain played an important role in MT assembly (50) (51) (52) . Brandt and Lee showed that truncated tau 231-441 could not nucleate or bundle MTs in vitro; however, the addition of residues 212-230 restored these abilities (50). Gustke et al. reported that a truncated tau construct containing just three repeats and C-terminal extensions had reduced MT assembly activity (51) . Deletion of the N-terminal projection domain, which has a spacer function, induced abnormally tight bundling (46, 50, 51) . Dixit et al. found that truncated forms of tau lacking the projection domain were stronger inhibitors of dynein and kinesin motor proteins than Tau-FL (52). Our results regarding the impairment of Tau-CTF24 in MT assembly is consistent with previous findings showing that MT assembly required not only repeat domains for elongation MTs, but also an additional N-terminus sequence (at least 212-242) for MT nucleation and bundling. We speculated that Tau-CTF24 could not nucleate and bundle MTs because of the lack of this N-terminal sequence. Further studies are needed to confirm whether Tau-CTF24 inhibits motor protein binding to MTs.
Tau can be degraded by the calcium-activated cytosolic cysteine protease, calpain (6, 53) . Calpain 1 and calpain 2, also known as μ-calpain and m-calpain, are two major isoforms in the central nervous system (54) . In tauopathies including AD, the active form of calpain 2 was shown to be co-localized with the hyperphosphorylated-tau protein under rare conditions (55) . The activation of calpain, as determined by the active form of calpain 1 or spectrin cleavage, was stronger in AD than in control brains (56, 57) . We found that the in vitro calpain cleavage of tau produced Tau-CTF24 in the lysates of SH-SY5Y cells expressing 2N4R tau, while calpain inhibitors suppressed the production of Tau-CTF24. Previous studies have already reported that the incubation of recombinant tau proteins with calpain generated 17-kDa and other sized fragments (58, 59) ; however, Tau-CTF24 only consisted of four-repeat domains and the C-terminal region has not yet been examined in detail in vivo. We performed a calpain cleavage prediction on the 2N4R tau sequence using multiple kernel learning on the CaMPDB website (60, 61) , and the site we identified by an MS analysis was consistent with one of the putative cleavage sites (Supplementary Material, Fig. S6 ). Eighty percent of the putative sites (19 out of 23 sites) were present in the N-terminal half of tau, excluding MT-binding repeats. An increase in Ca 2+ concentrations in degenerative neurons activates calpain and digests the N-terminal half of tau; however, the C-terminal half may remain as a constituent of neurofibrillary tangles. We also observed an increase in calpain activity with aging in the brains of Tg601 mice. These results were consistent with the previously established notion that calpain plays a crucial role in a number of neurodegenerative diseases including AD and Parkinson's disease (62) . The activation of calpain was previously reported not only in AD brains (56, 63) , but also in the cerebrospinal fluid of living AD patients (64). Rao et al. revealed that the hyperactivation of calpain in JNPL3 tauopathy model mice induced the breakdown of tau while the overexpression of CAST suppressed abnormal tau proteolysis (65) . However, further studies using calpain inhibitors or calpastatin-overexpressing mice are needed to confirm whether Tau-CTF24 in Tg601 brains is produced by calpain. Using a cell-based assay, we compared the intracellular aggregating activities of Tau-CTF24 and Tau-FL. The seeding activity of Tau-CTF24 was markedly stronger than that of Tau-FL. This cellbased assay consisted of three steps: synthetic aggregated tau or insoluble tau from diseased brains made contact with SH-SY5Y cells, entered the cell and further induced the aggregation of intracellular tau (66) . We found that aggregated Tau-24CTF was detected in the lysate fraction without any reagent 5 min after its addition. This result indicated that Tau-24CTF bound more rapidly than Tau-FL. Confocal microscopy images also revealed that the amount of attached Tau-24CTF was higher than that of Tau-FL. A previous study reported that the mechanism underlying the cellular uptake of tau aggregate seeds into neurons involved macropinocytosis (44) . This process is initiated by the binding of aggregated tau to HSPGs on the cell surface (44) . Tau is considered to be a heparin-binding protein (67) . In its soluble state, Tau has a paperclip conformation in which the C terminus folds near the repeat domain, and the N terminus folds back near the C terminus (32) . Since Tau-CTF24 lost the N-terminal half and partly broke the paperclip conformation, heparin may access the repeat regions of Tau-CTF24 more easily than Tau-FL. Tau-CTF levels in the pellet were higher than those of Tau-FL even 5 min after aggregated seeds had been added to cells. This result supported Tau-CTF24 making contact with cells more rapidly than Tau-FL. The binding of Tau-CTF24 was blocked by heparin (Fig. 7C) ; therefore, Tau-CTF24 and Tau-FL may also bind via HSPG. A charge-distribution plot showed that the N terminus was negatively charged while the C terminus was positively charged (68) . Tau-CTF24 was positively charged and, thus, bound more rapidly to the minus charged HSPG than Tau-FL. After Tau-CTF24 enters cells, it may induce further aggregation more efficiently than Tau-FL because the repeat domain generally aggregates more readily than Tau-FL (69) .
Exosomes are multivesicles that are released into the extracellular medium following the fusion of endosomal intermediates called multivesicular bodies to the plasma membrane (70) . Previous studies on cells overexpressing exogenous tau suggested that the release of tau might be mediated by exosomes and/or membrane vesicles (25, 26) . The release of tau proteins may represent a cellular mechanism by which to prevent toxic increases in its intracellular levels. Since Tau-24CTF readily detaches from MTs inside cells, the excess amount of Tau-24 CTF may be eliminated more rapidly than Tau-FL through this cellular mechanism. A recent study showed that oligomers of the repeat domain of tau caused a loss in spine density in cell models (69) . Tau-CTF24, which does not bind to MTs, also formed oligomers and acquired similar toxicity. Therefore, the release of tau from the inside of cells to the extracellular culture medium may be a cellular protective mechanism to avoid its toxicity. α-Synuclein was previously reported to be released from neuroblastoma cells via exosomes through a calcium-dependent process (71) . Our results indicated that the calcium-dependent enzyme, calpain, generated Tau-CTF24 in the Tg601 mouse brain. Therefore, the activation of calpain in degenerative cells may trigger the production of Tau-CTF24, leading to prion-like propagation (Fig. 8 ).
In conclusion, our results demonstrated the various toxic effects of Tau-CTF24, including loss of the promotion of MT assembly, marked aggregation and prion-like properties. Calpain-1 may be the enzyme responsible for cleaving the amino-terminal of Tau-CTF24. These results indicate that calpain is a potential therapeutic target in major tauopathies including AD.
Materials and Methods

Animals
Non-transgenic (Non-Tg) and tau transgenic (Tg601) mice expressing high levels of wild-type human tau (2N4R) under the control of the calcium/calmodulin-dependent protein kinase IIα 35 (CAMKIIα) promoter were used in the present study (31) . These mice were littermates and had the same genetic background, C57BL/6. All experiments were performed in accordance with the Guidelines for Animal Experiments of Juntendo University (Permit number: 260199). The procedures involving animals and their care conformed to the international guidelines set out in 'Principles of Laboratory Animal Care' (NIH publication no. 85-23, revised 1985).
Antibodies
The epitopes of the tau antibodies used in this study are described in the schema of Figure 1A . TauN, Tau-5 (Chemicon, Temecula, CA, USA), Exon 10v2, T46 (Invitrogen, Carlsbad, CA, USA) and TauC were phosphorylation-independent antibodies. TauN, Exon10v2 and TauC were raised against tau peptides corresponding to the epitopes. Mouse monoclonal antibodies to tau phosphorylation at Ser262 (12E8: Elan Pharmaceuticals) and rabbit polyclonal antibody ( pAb) to tau phosphorylation at Ser396 (Biosource, CA, USA) were also used. Other antibodies were obtained from the following sources: a monoclonal antibody (mAb) for GAPDH and α-spectrin (clone AA6) (Millipore); α-tubulin (DM1A) and acetylated α-tubulin (6-11B-1) (Abcam); a pAb for p35 (C-19) (Santa Cruz Biotechnology); pAb for calpastatin (4146S) (Cell Signaling Technology). Antibody for activated-calpain 1 ( post- 
Preparation of detergent-insoluble fractions from brains of mice and patients
Brain samples for immunoblot analyses were prepared as previously described (73) . Briefly, frozen brain tissues (0.2 g) were homogenized in 2 ml of homogenization buffer (HB: 10 m Tris-HCl, pH7.5 containing 0.8 M NaCl, 1 m EGTA and 1 m dithiothreitol) and centrifuged at 100 000g for 20 min at room temperature. The supernatants were harvested as TS-sup and the pellets were suspended in 2 ml of HB by sonication. Triton X-100 was added to the suspension (final concentration: 1%), which was then incubated for 30 min at 37°C and centrifuged 100 000g for 20 min at room temperature. The Triton X-soluble fractions (TX-sup) were harvested and the pellets were suspended in 1 ml of HB by sonication. Sarkosyl was added to the suspension (final concentration: 1%), which was then incubated for 30 min at 37°C and centrifuged 100 000g for 20 min at room temperature. The Sarkosyl-soluble fractions (Sar-sup) were harvested and the resulting pellets were used as the detergent-insoluble fraction ( ppt). The ppt was suspended in 0.1 ml of Sodium dodecyl sulfate (SDS) buffer by sonication for western blotting.
Western blotting
Fractions were diluted in SDS buffer and subjected to SDS-PAGE (SuperSep Ace 15% or 5-20%, Wako, Japan). Separated proteins were blotted onto polyvinylidene difluoride membranes (Immobilon-P, Millipore, Billerica, MA, USA). The blots were incubated at room temperature or 4°C overnight with the primary antibody, followed by the appropriate species biotinylated secondary antibody. The VECTASTAIN ABC Kit (VECTOR Laboratories, Burlingame, CA, USA) and DAB substrate (Dojindo, Japan) or ECL Prime Western Blotting Detection System (GE Healthcare) were used for visualization and blots were analyzed using Image J software (National Institutes of Health, Bethesda, MD, USA).
Liquid chromatography-ion trap mass spectrometry (LC-MS/MS)
Samples were resuspended in 0.1% formic acid containing 2% acetonitrile and subjected to a DiNa HPLC system fit with an automatic sampler (KYA Technology, Japan). A reverse-phase capillary column (Develosil ODS-HG5, 0.075 mm × 150 mm, Nomura Chemical Co., Ltd, Seto, Japan) was used at a flow rate of 300 nl/ min with a 2-80% linear gradient of acetonitrile for 60 min. The eluted peptides were directly detected with the ion trap mass spectrometer, Velos Pro (Thermo Fisher Scientific Inc.), at a spray voltage of 1.9 kV and collision energy of 35%. The mass acquisition method consisted of one full MS survey scan followed by an MS/MS scan of the most abundant precursor ions from the survey scan. Dynamic exclusion for the MS/MS scan was set to 30 s. Data were analyzed with Mascot (Matrix Science Inc., Boston, USA) software.
Recombinant tau protein preparation
Human tau cDNA in the bacterial expression plasmid pRK172 was used to produce recombinant proteins (74) . Wild-type tau (tau1-441) and the truncated C-terminal tau fragment (tau243-441) were constructed by PCR with the primers 5′-CGGGATCCATGG CTGAGCCCCGCCAGGA-3′ (BamHI-sense) for tau1-441, 5′-CGGGAT CCATGCTGCAGACAGCCCCCGT-3′ (BamHI-sense) for tau243-441 and 5′-CGGAATTCTCACAAACCCTGCTTGGCCA-3′ (EcoRI-antisense) for each. Tau proteins were expressed in Escherichia coli BL21 (DE3) and purified as described previously (75) .
Tau filament assembly assay
The purified recombinant tau protein (10 µM) and heparin (0.1 mg/ml) were incubated at 37°C for 72 h in 100 µl of 30 m Tris-HCl, pH 7.5, containing 0.1% sodium azide and 20 m dithiothreitol (DTT) (67) . In order to quantitatively evaluate the formation of filaments, aliquots (20 µl) of assembly mixtures were mixed to 300 µl of 20 m MOPS, pH 6.8, containing 5 µM ThS (Sigma) and ThS fluorescence was measured at various time points using FlexStation II (Molecular devices) (set at 436 nm excitation/535 nm emission) (76) .
Microtubule assembly assay
Recombinant tau proteins were incubated with 30 µM bovine brain tubulin (Cytoskeleton, Denver, CO, USA) in PEM buffer (containing 0.5 m guanidine triphosphate and 1 m dithiothreitol) at 37°C as described previously (75) . The assembly of tubulin into MTs was monitored over time by a change in turbidity at 350 nm.
Cell culture and transfection
SH-SY5Y cells and N2a cells were cultured in DMEM/F-12 medium (Sigma) and RPMI 1640 medium (life technologies) with 10% fetal bovine serum, respectively. These cells were maintained at 37°C under a humidified atmosphere of 5% CO 2 in air. They were cultured to 50% confluence in six-well culture plates for transient expression and then transfected with 1 µg/well of the expression vector using FuGENE6 (Promega).
MT bundling activity analysis
Neuro2a cells on coverslips were transfected with the indicated plasmids and cultured for 24 h as described above. After fixation with 4% paraformaldehyde, cells were stained with the appropriate primary antibodies and secondary antibodies labeled by Alexa Fluor 488 or 555 fluorescein (Life Technologies). Fluorescence was analyzed with a laser scanning confocal fluorescence microscope (TCS-SP5; Leica).
In vitro calpain cleavage assay SH-SY5Y cells in six-well culture plates were transfected with the human tau (2N4R) expression vector and cultured for 24 h as described above. After washing with PBS, cells were homogenized by sonication in 100 µl/well of extraction buffer (50 m HEPES, pH7.5, 1 m EDTA, 100 m NaCl 2 , 10 m DTT and 0.1% CHAPS). The homogenate was centrifuged at 16 000g for 20 min at 4°C. The supernatant was incubated at 30°C with 1.5 units of calpain-I (Calbiochem) in extraction buffer with or without 5 m CaCl 2 . The reaction was stopped by the addition of SDS sample buffer and the sample was boiled at 100°C for 5 min immediately before SDS-PAGE and western blotting analyses (40) .
Immunohistochemistry
Immunohistochemistry was performed as previously described by Kambe et al. (31) . Mice were killed by cervical dislocation and brains were fixed in Bouin solution. Six-micrometer-thick Human Molecular Genetics, 2015, Vol. 24, No. 22 | 6413 coronal sections were obtained from each paraffin block and autoclaved at 121°C for 10 min in PBS solution for antigen retrieval. The sections were treated with 3% H 2 O 2 to quench endogenous peroxidase. Staining of the sections was performed overnight at 4°C using rabbit anti-post-calpain I (1:500) for the primary antibody. Sections were then incubated with biotinylated goat anti-rabbit IgG (1:100, Dako) for 60 min at RT, followed by incubation with streptavidin-HRP (1:300, Dako) for 30 min at RT. The sections were then examined under a microscope (Zeiss) after staining with DAB and HE.
Introduction of proteins into cells
The introduction of aggregated proteins into SH-SY5Y cells was performed as previously described (73) . Briefly, aggregated tau filaments or detergent-insoluble fractions from human brains were suspended in 20 m Tris-HCl ( pH 7.5). Two to five micrograms of protein was then diluted in 125 µl of 20 m Tris-HCl, and 62.5 µl of MultiFectam (Promega) was added. After being incubated for 30 min at room temperature, 62.5 µl of Opti-MEM was added and the incubation was continued for 5 min at room temperature. The mixture was then added to SH-SY5Y cells expressing Tau-FL or Tau-CTF24 and incubated at 37°C for 6 h in a CO 2 incubator. The medium was then changed to fresh medium and the culture was continued for 48 h. Cells were harvested and detergent-insoluble fractions were prepared as described above.
Statistical analysis
Statistical analyses were performed using JMP8 software (SAS Institute Japan). We used unpaired Student's t-test for comparison between two sample groups. One-way ANOVA followed by the Tukey test was performed for multiple comparisons. A P-value of <0.05 was considered to be significant.
Supplementary Material
Supplementary Material is available at HMG online.
